Alkermes plc. — Director's Dealing 2015

Oct 7, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alkermes plc. (ALKS)
CIK: 0001520262
Period of Report: 2015-10-05

Reporting Person: FRATES JAMES M (SVP & CFO, Alkermes plc)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-10-05	Ordinary Shares	A	5000	—	Acquired	53713	Direct
2015-10-05	Ordinary Shares	F	2356	$59.77	Disposed	51357	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-10-05	Performance Restricted Stock Units	$	A	5000	Acquired		Ordinary Shares (5000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	4000	Indirect
Ordinary Shares	50801	Indirect
Ordinary Shares	41423	Indirect

Footnotes

F1: Shares held by James M. Frates Grantor Retained Annuity Trust dated March 14, 2014 (the "GRAT"). The Reporting Person is a trustee and beneficiary of the GRAT and may be deemed to hold voting and dispositive power with regard to the reported shares held by the GRAT.

F2: Shares held by the 2015 GRAT. The Reporting Person is a trustee and beneficiary of the 2015 GRAT and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2015 GRAT.

F3: Each performance restricted stock unit represents a contingent right to receive one ordinary share of Alkermes plc.

F4: Represents the earned but unvested portion of the performance restricted stock units granted to the reporting person on March 3, 2014. Fifty percent of the earned performance restricted stock units vested on October 5, 2015 and are included in Table I of this Form 4; the remaining fifty percent of the earned performance restricted stock units are included in Table II of this Form 4 and will vest on October 5, 2016. The performance restricted stock units were earned based on the Food and Drug Administration's approval of ARISTADA? (aripiprazole lauroxil).